Recent Events & Catalysts
10x Genomics, Inc. (TXG) — real, dated facts. Not a claim about what caused any single day's price move.
Committee Signals
Proprietary signals generated by the Innellis AI committee — score changes, rating shifts, and analyst disagreements.
No committee signals recorded yet.
News
Piper Sandler Maintains Neutral on 10x Genomics, Raises Price Target to $47
Benzinga · 1d ago
Canaccord Genuity Maintains Buy on 10x Genomics, Raises Price Target to $60
Benzinga · 1d ago
Citigroup Maintains Neutral on 10x Genomics, Raises Price Target to $50
Benzinga · 4d ago
Morgan Stanley Maintains Equal-Weight on 10x Genomics, Raises Price Target to $40
Benzinga · 4d ago
10x Genomics, Inc. (TXG) Q2 2026 Earnings Call Transcript
SeekingAlpha · 4d ago
10x Genomics Raises FY2026 Sales Guidance from $600.000M-$625.000M to $610.000M-$630.000M vs $613.851M Est
Benzinga · 5d ago
10x Genomics Q2 EPS $(0.14) Beats $(0.24) Estimate, Sales $151.000M Beat $146.788M Estimate
Benzinga · 5d ago
10x Genomics Partners With Lausanne University Hospital On Diagnostic Applications Of Single Cell And Spatial Technologies For Cancer Care
Benzinga · 13d ago
SEC Filings (90 days)
Results of operations (earnings release), Financial statements and exhibits
Filed 2026-08-06 · 5d ago · Material
Submission of matters to a vote of security holders
Filed 2026-06-08 · 64d ago
Earnings
No recent earnings data available.
Latest Analyst Action
No recent analyst actions available.